Jazz’s cannabidiol therapy flunks in Japanese Phase III trial

Jazz Pharmaceuticals’ efforts to get its cannabidiol therapy approved in Japan have hit a snag after a Phase III trial in Japan evaluating the therapy failed to meet its primary endpoint.